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C 
Ytotoxic T lymphocyte-assodated molecule-4 (CTLA-4) 
is a lymphocyte cell surface receptor originally discov- 
ered in a search for molecules having a role in T cell cytotox- 
icity (1). This molecule is a member of the immunoglobulin 
superfamily  and  is  homologous  to  another  T  cell surface 
receptor,  CD28.  Both CD28  and CTLA-4 bind the  same 
counter-receptors, members of the B7 family on APCs. While 
the role of CD28 during T cell responses to antigen has been 
well studied, much less is known about the role of CTLA-4. 
Recent studies on the function of this molecule have been 
controversial and have yielded seemingly conflicting results. 
In this issue,  a new study (2) provides further evidence on 
the function of this molecule and lends support to growing 
evidence that CTLA-4 is a receptor having unique function 
during an immune response. What follows in this article is 
an account of the development of this story, an analysis  of 
the significance of the new data, and a discussion of potential 
fruitful areas  of future research  on CTLA-4. 
Role of  B7 Molecules in T Cell Costimulation.  The interac- 
tions of T lymphocytes with APC are key to the generation 
of an immune response to foreign pathogens,  transplanted 
organs,  or  to  self tissue during  autoimmune  disease.  The 
specificity of these T  cell-APC interactions  is provided by 
the  recognition  of antigenic  peptide-MHC  complexes by 
clonotypic TCR. However, TCR engagement alone gener- 
ally does not lead to full T  cell activation, but may instead 
lead to T  cell clonal anergy. A  successful immune response 
requires additional interactions between the T  cell and the 
APC. These costimulatory interactions  thus determine the 
outcome of TCR engagement, i.e., whether this engagement 
activates  or  inactivates  subsequent  immune  responses  (3). 
While the molecular nature of these costimulatory interac- 
tions is not fully understood,  it is now clear that  a key T 
cell costimulatory signal is provided by interaction of CD28 
receptors on T cells with B7 counter-receptors on APC (4). 
Engagement of the CD28 receptor by B7 molecules triggers 
a signaling  pathway that  regulates T  cell cytokine produc- 
tion, particularly I1,-2 (4). Two B7 molecules are known, B7-1 
(CD80) and B70/B7-2  (CD86), each of which binds CD28 
with similar avidity and elicits similar functional effects (5). 
CTLA-4.  CTLA-4 is a second high avidity receptor for 
B7 molecules that was cloned from a subtracted cytolytic T 
cell cDNA library (1, 6). CTLA-4 transcripts were detected 
in activated lymphocytes and were coinduced with T cell cytox- 
icity.  Human and mouse genes encoding CTLA-4 map to 
the  same chromosomal band  as CD28  (7,  8),  and human 
CTLA-4 and CD28 have been linked at the molecular level 
on  a  yeast  artificial  chromosome  clone  (9).  Recombinant 
soluble CTLA-4 binds CD80 and CD86 with higher avidity 
than  recombinant  soluble CD28  (5,  10). 
Although originally identified as a cytolytic T cell-associated 
molecule,  CTLA-4  transcripts  have been detected in both 
CD4 + and CD8 + T  cell clones (11). Cell surface expression 
of CTLA-4 on activated T cells has been detected using specific 
mAbs. In human T  cells (12),  CTLA-4 is expressed equally 
on CD4 + and CD8 + T  subsets of activated T cells, whereas 
with  murine  cells,  CTLA-4  expression  is  higher  on  the 
CD8 + subset (13).  Expression of CTLA-4 is highly activa- 
tion dependent; CTLA-4 is not detected on resting cells but 
is induced during T  cell activation (1, 11-13).  Expression is 
regulated in part by levels of mRNA (1, 11). With activated 
human  T  cells,  maximal  CTLA-4  protein  expression  was 
"~2-3% of CD28 (12).  CTLA-4 is therefore a high avidity, 
low abundance receptor  for B7 molecules. 
Functions of CTLA-4 during T  Cell Activation.  Relatively 
little is known of the role of CTLA-4 during T  cell activa- 
tion, and the few experiments reported are largely contradic- 
tory.  Complete conservation was noted in  the  amino  acid 
sequences of the cytoplasmic tails of murine and human homo- 
logues of CTLA-4 (14). Since the cytoplasmic tail of CTLA-4 
presumably mediates signal transduction,  this sequence con- 
servation suggested that CTLA-4 has an important conserved 
signaling  function.  The  cytoplasmic tails  of CTLA-4  and 
CD28 show more limited sequence homology (7), so it was 
therefore difficult to predict from sequence comparisons alone 
whether CTLA-4 would have similar or different functions 
than  CD28. 
Initial  experiments  (12)  showed  that  combinations  of 
CTLA-4 mAb and anti-CD28 mAb or Fab fragments were 
synergistic in blocking adhesion of activated CD4 + lympho- 
cytes to CDS0-transfected CHO cells, and in blocking T cell 
proliferation  during  a mixed lymphocyte reaction  (MLR). 
Anti-CTLA-4 mAb had weak costimulatory activity together 
with anti-TCR mAb on previously primed CD4 § T  cells, 
but the effects were less than those observed with anti-CD28 
mAb  plus  anti-TCR  mAb.  Combinations  of  suboptimal 
amounts  of anti-TCR  mAb,  anti-CD28  mAb  plus  anti- 
CTLA-4 mAb were synergistic in their costimulatory ability 
(12). Another study from this group (15) extended the original 
findings  and showed that the cooperative costimulatory effects 
of anti-CTLA-4 and anti-CD28 mAbs were greatest at low 
concentrations of anti-CD28 mAb (and, hence, low occupancy 
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to the proposal that CD28 and CTLA-4 cooperatively regu- 
late T  cell activation  and costimulation  by B7 molecules. 
A more recent study by Walunas et al. (13) suggested that 
CTLA-4 can also serve as a negative regulator of T cell acti- 
vation. These investigators  showed that in contrast to previous 
studies  with  human  lymphocytes,  anti-CTLA-4  mAb in- 
creased T cell proliferation in murine MLIL. Similar results 
were obtained with Fab fragments  of anti-CTLA-4  mAb. 
These results were interpreted  to mean that  anti-CTLA-4 
mAb elicited its stimulatory effects by blocking interactions 
of CTLA-4 with its natural ligand,  an interaction that was 
inhibitory for T  cell proliferation  in the MLR.  Additional 
support  for  this  proposal came from  the  observation that 
anti-CTLA-4 mAb inhibited proliferation of T cells costimu- 
lated with  anti-CD3  and anti-CD28  mAbs.  These studies 
led to the proposal that CTLA-4 interaction with its natural 
ligand  downregulates  an immune  response. 
Another recently published study (16) also suggested an 
antagonistic function for CTLA-4. These authors showed that 
anti-CTLA-4  mAbs triggered  antigen-specific apoptosis in 
previously activated human T ceils. With naive T cells, how- 
ever, anti-CTLA-4 mAbs provided agonistic effects to com- 
binations of anti-CD3 and anti-CD28 mAbs. Thus, the effects 
of anti-CTLA-4  mAbs were determined  by the activation 
state of the cells  studied. 
Thus,  these initial  studies have led to two different and 
distinct models for the role of CTLA-4 in T  cell activation 
(Fig.  1). In one model, CD28 and CTLA-4 function cooper- 
atively to upregulate T  cell activation;  in the other model, 
CTLA-4 antagonizes CD28 and downregulates T  ceil acti- 
vation. 
The new study by Krummel and Allison (2) provides new 
data on the function of CTLA-4.  These authors  show that 
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Summary of properties  of T cell surface receptors CD28 and 
CTLA-4: expression, binding, and functional properties. The subunit struc- 
ture of CD28 and CTLA-4 receptors is indicated  schematically; each is 
homodimeric. The relative positions of inter- and intramotecuhr disulfide 
bonds  of CD28 and CTLA-4 are depicted.  Differences are emphasized in 
functional  properties  of CD28 and CTLA-4 as indicated by studies using 
specific mAbs. 
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plastic wells, anti-CTLA-4 and anti-CD28 mAbs were syn- 
ergistic in their ability to costimulate the proliferation of mu- 
rine  T  cells.  These  data  were  interpreted  to  mean  that 
anti-CTLA-4  mAb blocked an inhibitory  effect on T  cell 
proliferation caused by interaction between endogenous B7 
molecules on T cells with CTLA-4. Other experiments showed 
that cross-linking  of anti-CD3  plus anti-CD28  mAhs had 
a powerful costimulatory effect on T cell proliferation, cross- 
linking of anti-CTLA-4 mAb together with the other anti- 
bodies inhibited T cell proliferation. When the TCR, CD28, 
and  CTLA-4  mAbs  were  immobilized  on  plastic  beads, 
anti-CTLA-4 mAbs inhibited the proliferative effects of anti- 
CD28  plus  anti-CD3  mAbs.  Increasing  amounts  of anti- 
CTLA-4  mAbs  progressively  inhibited  the  costimulatory 
effects of anti-CD28  mAbs. 
Thus, anti-CTLA-4 mAbs can either stimulate or inhibit 
T cell activation, depending on experimental conditions. The 
study by Krummel and Allison demonstrates several factors 
that  are critical for determining  the direction of the effects 
of anti-CTLA-4  mAbs.  These include the endogenous ex- 
pression of B7 by T  cells.  A mixture of mAbs to B7-1 and 
B7-2 showed similar stimulatory effects as anti-CTLA-4 mAb 
when the TCR signal was provided by mAb immobilized 
on plastic wells. Since B7-2 was expressed at low (nonstimula- 
tory) levels on the T cells used in these experiments, T cell- 
T  cell  interactions  mediated  by  interaction  of B7-2  and 
CTLA-4 may have been inhibitory for T  cell proliferation. 
It is unclear how endogenous expression of B7 affects the 
inhibitory  effects  of anti-CTLA-4  mAbs seen under other 
conditions. Also, the degree of co-cross-link/ng of CD3, with 
CD28, and/or CTLA-4 was important for determining the 
extent of proliferation. Taken together, the data suggest that 
the outcome of the T  cell antigen receptor engagement  is 
determined  by  integration  of signals  provided  by  CD28 
and CTLA-4. 
What do these findings tell us about the role of CTLA-4 
in T cell activation? Perhaps most simply, they suggest that 
stimulation of CD28 and CTLA-4 TCRs may have different 
effects on T  cell activation.  Does this mean that  CTLA-4 
and CD28 have intrinsically  opposite effects  during T  cell 
activation?  Not  necessarily.  Experience  in  other  signaling 
systems has  taught us that it is quite common for receptor 
triggering to be context dependent, i.e., opposite effects are 
elicited under different experimental conditions. For example, 
it has long been known that  cytokines and their receptors 
are muhifunctional (17); many cytokines can stimulate prolifer- 
ation under certain conditions and inhibit under others. The 
reasons for these different effects  are not fully understood, 
but may involve differences in receptor occupancy, coupling 
to the signal transducing  receptors,  or the presence or ab- 
sence of other cofactors. We should keep in mind that, gener- 
ally speaking, a receptor that has only one effect is one that 
has not been fully studied.  Perhaps the main message from 
the studies of Krummel and Allison is that CTLA-4 has come 
of age. Thus, we now realize that CTLA-4 is a receptor with 
its own unique properties  and its own mechanisms  of in- 
tegrating with the lymphocyte signal transduction machinery. 
Future Directions.  As usual, coming of age means that life becomes more complicated. The studies of Krummel and Al- 
lison also indicate that  the process of T  cell costimulation 
is more complicated  than  previously imagined,  and  more 
highly regulated. Since CTLA-4 and CD28 are coexpressed 
on the same cells and share common ligands,  their engage- 
ment cannot be considered as independent  events. The net 
result of engagement of CD28 and CTLA-4 receptors by B7 
ligands will be determined by (a)  the different affinities  of 
CTLA-4 and CD28 for their B7 ligands; (b) the different ex- 
pression levels of CTLA-4 and CD28; and (c) different effects 
of signaling through these two receptors (Fig.  1). How these 
factors are integrated by the lymphocyte signaling machinery 
is largely unknown  at  this juncture. 
Future experiments will be necessary to more fully eluci- 
date the roles  of signals  through  the  CTLA-4  and  CD28 
receptors.  Perhaps all  the reported experimental results are 
correct  but  their  validity  is  limited  to  the  particular  ex- 
perimental conditions that have been used. Further in vitro 
studies with human and murine T cells may help clarify the 
different effects of anti-CTLA-4 mAbs. One area that needs 
clarification is whether CTLA-4 has different functions  in 
the different lymphocyte subsets used by different groups or 
in different species. Another area is whether mAbs to different 
epitopes on CTLA-4 have different effects. Undoubtedly, gene- 
targeted disruptions of CD28 and CTLA-4 genes will be valu- 
able in future studies. CD28 knockout mice are defective in 
certain but not other immune responses (18).  It will be im- 
portant to determine the role of CTLA-4 in these mice. One 
study (19) suggested that CTLA-4 did not function in vitro 
when lymphocytes from these mice were studied, but more 
needs to be done,  particularly  during  in vivo immune  re- 
sponses.  A  report  on the properties  of CTLA-4 knockout 
mice is eagerly awaited. Perhaps other transgenic studies will 
also be useful.  If CTLA-4  triggering  has  a negative effect 
on T  cell activation in vivo, then constitutive expression of 
CTLA-4 on transgenic T  cells should have a negative effect 
on the immune  responses of such animals. 
Finally, a more complete understanding of the signal trans- 
duction pathways of CTLA-4 and CD28 receptors is needed. 
While  there is a tendency to attribute  some of the effects 
of anti-CTLA-4  mAbs as evidence for a "negative signal" 
transmitted by this receptor (2,  13), it is unclear what this 
term means. Despite the importance of CD28 receptor trig- 
gering during T cell activation, relatively little is known of 
its signal transduction pathway(s) and even less is known of 
pathway(s) used by CTLA-4. It is perhaps typical of our state 
of knowledge about CTLA-4 that the two published studies 
(20, 21) on its signaling have given conflicting results. Both 
of these studies examined whether CTLA-4 triggering stimu- 
lated association of PI-3 kinase with a Y-X-X-M motif in its 
cytoplasmic tail, as has been demonstrated with a similar motif 
in the CD28 cytoplasmic tail (reviewed in reference 22). Stein 
et al. (20) found that CDS-CTLA-4 cytoplasmic tail chimeric 
constructs did not associate with the p85 subunit of PI-3 ki- 
nase after stimulation with mAb. The analogous CD8-D28 
cytoplasmic tail constructs did associate with PI-3 kinase after 
triggering. In contrast, Schneider et al. (21) showed that trig- 
gering with mAbs of native CTLA-4 in a T  cell line led to 
PI-3 kinase association with CTLA-4 and activation of PI-3 
kinase activity, similar to what has been reported for the CD28 
receptor (22).  Clearly more must be done to elucidate the 
signal transduction pathway(s) of CTLA-4, and to determine 
how this pathway(s) compares with  that  of CD28. 
Over the last  several  years,  the CD28/CTLA-4/CD80/ 
CD86 receptor system has emerged as a key control point 
in the pathway(s) leading to T cell activation during immune 
responses.  Blockade of this pathway leads to immunosuppres- 
sion,  prolongs organ graft  acceptance,  and ameliorates au- 
toimmune disease in rodent models (23, 24); stimulation of 
this pathway can facilitate immune rejection of tumors (25). 
Now that the importance of this system has been established, 
we are beginning  to unravel its molecular details.  We have 
begun to appreciate that  each of the players in this system 
has evolved unique characteristics that contribute to the ex- 
quisite regulation of this powerful system. The flurry of re- 
cent studies on the CTLA-4 receptor signifies  the beginning 
of our understanding of the role of this fascinating molecule 
in T  cell immune  responses. 
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